KRMD

KORU Medical Systems announced its First Quarter 2026 financial results on May 6, 2026, reporting a 22% increase in net revenues to $11.8 million over the prior year period, with gross profit growing 20% to $7.2 million and net loss improved by 31% to ($0.8) million. In March 2026, KORU Medical Systems announced receiving EU MDR Certification for its Freedom60® Infusion Pump, including compatibility with prefilled syringes, which is significant for its international expansion and a CEO transition was also announced. In November 2025, the company reported a 27% revenue growth for the Third Quarter 2025 and raised its full-year 2025 revenue guidance. The stock price as of April 20, 2026, was $4.26 per share, representing a 90.18% increase from $2.24 per share on April 21, 2025. Over the past 52 weeks, KRMD has traded between a low of $2.63 and a high of $6.61.